Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography

被引：58

作者：

Deloar, HM ^{[1
]}

Fujiwara, T ^{[1
]}

Nakamura, T ^{[1
]}

Itoh, M ^{[1
]}

Imai, D ^{[1
]}

Miyake, M ^{[1
]}

Watanuki, S ^{[1
]}

机构：

[1] Tohoku Univ, Ctr Cyclotron & Radioisotope, Aoba Ku, Sendai, Miyagi 980, Japan

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1998年 / 25卷 / 06期

关键词：

L-[methyl-C-11]methionine; whole-body positron emission tomography; cumulated activity; absorbed dose; MIRD method;

D O I：

10.1007/s002590050265

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

L-[Methyl-C-11]-methionine (C-11-methionine) is proposed as a useful radiotracer for tumour diagnosis. Human biodistribution data of cumulated activities and absorbed doses estimated by the MIRD (medical internal radiation dosimetry) method for C-11-methionine are not available in the literature. In this study we measured the organ activity for C-11-methionine by using whole-body positron emission tomography (PET) and estimated the absorbed doses to 25 organs by the MIRD method. Whole-body dynamic PET scans were per formed on five normal volunteers to measure the time course of the organ activity concentration (activity/volume) after intravenous administration of C-11-methionine. Cumulated activities of the ten source organs were calculated fi om the time-activity curves, obtained from the dynamic PET data, Absorbed dose estimates were performed by the MIRD method for the Caucasian reference man and for the Japanese reference man. The organs which received the highest absorbed doses for the Caucasian reference man were found to be the bladder wall (2,7x10(-2) mGy/MBq), the pancreas (1.9x10(-2) mGy/ MBq), the liver (1.8x 10(-2) mGy/MBq) and the kidney (1.1x10(-2) mGy/MBq). The effective doses for the Caucasian reference man and the Japanese reference man were calculated as 5.2x10(-3) and 5.0x10(-3) mSv/MBq, respectively.

引用

页码：629 / 633

页数：5

共 10 条

[1]

COMAR D, 1976, EUR J NUCL MED, V1, P11

[2]

Cristy M, 1987, ORNL/TM-8381 V1-V7

[3]

Deloar HM, 1997, J NUCL MED, V38, P1603

[4]

DOWD MT, 1991, J NUCL MED, V32, P707

[5]

Fujiwara T, 1997, Ann Nucl Med, V11, P307

[6] QUANTIFICATION OF THE WHOLE-BODY DISTRIBUTION OF PET RADIOPHARMACEUTICALS, APPLIED TO 3-N-([F-18]FLUOROETHYL)SPIPERONE [J].

HERZOG, H ;

COENEN, HH ;

KUWERT, T ;

LANGEN, KJ ;

FEINENDEGEN, LE .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1990, 16 (02) :77-83

[7]

HONGO S, 1992, PRESENT STATUS INTER, P17

[8]

MEJIA AA, 1991, J NUCL MED, V32, P699

[9]

STALNACKE CG, 1984, THESIS U UPS, P1

[10]

TANAKA G-I, 1988, Nippon Acta Radiologica, V48, P509

← 1 →